ANDOVER, Mass., Jan. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion Capital on January 10, 2025. In response, the company issued the following statement: We strongly believe that the claims made in the Scorpion Capital report ...

In this video, I will talk about TransMedics (TMDX -5.16%) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Jan. 10, 2025. The video was published on Jan. 10, 2025. ...

Shares of TransMedics Group (TMDX -11.36%) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came after activist short seller Scorpion Capital released a scathing report about TransMedics.Scorpion stated in its report, "TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients -- the terminally ill, desperate for an organ." The short seller alleged that Tr ...

Shares of Transmedics (TMDX 9.47%) fell 28.1% in December, according to data from S&P Global Market Intelligence.The stock was already down significantly from its highs heading into the month following a weaker-than-expected October earnings report, so December events added insult to injury. Here's what happened to the former high flier. A cruel DecemberOn Dec. 2, Transmedics announced it had appointed Gerardo Hernandez as CFO, replacing current CFO Stephen Gordon effective immediately. Gordon will stay on ...

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise.As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vas ...

Leading organ transplant technology provider TransMedics (TMDX 3.90%) increased sales by more than 100% in 10 straight quarters from early 2022 to mid-2024. However, after delivering revenue growth of "only" 64% in its latest quarter -- while lowering guidance for a 35% increase in the upcoming fourth quarter -- the company has seen its stock plummet roughly 63% from its highs.As substantial as TransMedics' stock sell-off has been, its underlying business is by no means 63% worse. And remember, this adverse ...

I have rarely owned healthcare stocks over the years. Not because you can't make tons of money in the sector (quite the contrary), but because I want to really understand the companies I own, and the truth is, I have no expertise inHe is a contributing author to the investing group Wheel of Fortune where they share actionable trading ideas across all asset-classes, sectors and industries. The goal of the service is to provide a one-stop-shop for investment and portfolio ideas, while educating the vibrant co ...

ANDOVER, Mass.  , Dec. 23, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 2:15 p.m. Pacific Standard Time / 5:15 p.m. Eastern Standard Time. Event: 43rd A ...

Stock Performance - TransMedics Group Inc (TMDX) shares have plunged 57.5% in the past three months, significantly underperforming the industry's 3.6% decline and the S&P 500's 8.1% growth [1] - The stock's performance has been bleak compared to peers like Medtronic plc (MDT), GE HealthCare Technologies Inc (GEHC), and Abbott Laboratories (ABT), which saw declines of 8.5%, 6.8%, and 3.6% respectively over the same period [6] Financial Performance - The company reported robust improvement in both top and bottom lines in Q3 2024, driven by increased utilization of the Organ Care System (OCS) across all three organs and additional revenues from logistics services [3] - TransMedics narrowed its 2024 revenue outlook to $428 million-$432 million, representing 77-79% growth from 2023, compared to the prior outlook of $425 million-$445 million [8] - Estimates for 2024 earnings have moved 18% south to $1.00 in the past 60 days [18] Business Developments - TransMedics appointed Mr Gerardo Hernandez as CFO, effective Dec 2, 2024 [2] - The company remains on track to achieve its target of 10,000 OCS transplant cases per year in the US by 2028 [4] - TransMedics' OCS is the only FDA-approved, portable, multi-organ, warm perfusion technology platform, with three products (OCS Heart, OCS Lung, OCS Liver) receiving pre-market approval [9] Market Position and Strategy - The company has developed strong clinical relationships with leading academic medical centers worldwide through participation in clinical trials and commercial utilization of its products [12] - TransMedics' NOP expansion includes 100% owned and operated private aircraft dedicated to organ retrieval, improving efficiency in organ procurement [11] - The OCS has been reimbursed by CMS and private insurers, with the company developing expertise in transplant reimbursement and billing [13] Product Development - TransMedics has a long history in warm machine perfusion for organ preservation and continues to add technological and usability enhancements to its devices [15] - The company plans to develop newer versions of its technology to improve ease of use, portability, and capability [15] Valuation - TransMedics' forward 12-month P/S of 4.1X is lower than the industry average of 4.5X and its five-year median of 9.9X [16] Growth Prospects - The company's strong core growth prospects and favorable Zacks Style Score with a Growth Score of B suggest continued uptrend potential [21][22] - Despite current stock performance, the company's core business strength, earnings prowess, and robust financial footing present favorable long-term opportunities [21]

In today's video, I will discuss recent updates about TransMedics (TMDX -2.36%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Dec. 10, 2024. The video was published on Dec. 11, 2024. ...